Research progress on the drug therapy with C-ros proto-oncogene 1-receptor tyrosine kinase rearrangement in non-small cell lung cancer
C-ros proto-oncogene 1-receptor tyrosine kinase(ROS1)rearrangement occurs in 0.9%to 2.6%of non-small cell lung cancers(NSCLC),and the main treatments are targeted therapy,chemotherapy,and immunotherapy.Targeted therapies are the most commonly used therapies with clear efficacy,and the use of tyrosine kinase inhibitor(TKI)in ROS1-rearranged NSCLC can significantly improve the prognosis.Both crizotinib and entrectinib,which are currently used in the first-line treatment of ROS1-rearranged NSCLC,are prone to drug resistance,so progeny TKI that are sensitive to crizotinib have been developed for the resistance site of crizotinib,such as lorlatinib,repotrectinib,brigatinib,cabozantinib and taletrectinib.With the improved intracranial efficacy of the new generation of TKI,ceritinib and loratinib are expected to become first-line treatment options,but further studies are still needed.All patients will experience disease progression with TKI therapy,so understanding the mechanisms of acquired resistance is critical to determining the best sequential therapy.After TKI failure,exploring the potential efficacy of immuno-chemotherapy combinations has become a new direction for clinical research.This article reviews the relevant therapeutic approaches(targeted therapy,chemotherapy,immunotherapy)and their research progress in patients with ROS1-rearranged NSCLC in order,to provide a reference for clinical treatment.
NETL
NSTL
万方数据
